Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the most important drug attributes surveyed infectious disease specialists seek in a drug to treat severe Candida infections in the hospital setting are activity against Candida albicans and non-albicans species and fungicidal activity. Candida albicans is the most common species involved in these invasive fungal infections, but the prevalence of non-albicans species has been rising.

"Given the severity of severe Candida infections, surveyed physicians expressed the need for drugs with fungicidal activity against Candida strains that can eradicate the infection and prevent the condition from worsening," said Lisa Arias, analyst. "Additionally, because treatment for severe Candida infections is largely empiric, physicians need agents that possess potent, broad-spectrum activity against suspected pathogens. Timely, appropriate empiric therapy plays a significant role in the successful treatment of these infections."

In the new report entitled Hospital Anti-Infectives Insight Series: Severe Candida Infections, surveyed infectious disease specialists anticipate several events that could influence the treatment of severe Candida infections in the future. Nearly all surveyed specialists believe there will be a significant increase in azole-resistant Candida infections, which emphasizes the need for novel drugs to treat resistant Candida strains. They also expect a rise in bloodstream infections caused by Candida. These events will likely impact prescribing trends and result in increased use of newer antifungals, such as Pfizer's Vfend and the echinocandins (such as Merck's Cancidas, Astellas's Mycamine and Pfizer's Eraxis) in order to target infections due to resistant Candida strains.

About the Report

AMR's Hospital Anti-Infectives Insight Series: Severe Candida Infections analyzes hospital antifungal prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with primary research and extensive understanding of emerging therapies and forecasts. This report contains U.S. data and examines the reasons behind physicians' product preferences, factors driving hospital antifungal prescribing patterns and receptivity to emerging antifungals.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Arlington Medical Resources

CONTACT: Christopher Comfort of Decision Resources, Inc.,

Vivus's Qnexa Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment of Obesity

View Now